In the SELECT trial, patients did not enroll for the specific purpose of weight loss and received standard of care covering management of CV risk factors, including medical treatment and healthy lifestyle counseling, but without a specific focus on weight loss
Local Manufacturing And Fill-Finish Investments Lower Supply Risk Novo Nordisks USD 1.09 billion upgrade to its Montes Claros complex, announced in April 2025, will begin producing GLP-1 pens domestically in late 2026, shielding the Latin America GLP-1 agonists market from future import bottlenecks
The new generation of weight loss drugs: The pros and cons of GLP-1s The University of Kentucky Public Relations and Strategic Communications Office provides a weekly health column available for use and reprint by news media
309 The mechanism of dilated cardiomyopathy may involve increased apoptosis in cardiomyocytes regulated by the p53 pathway
Life Sci 2000
Some people dont like to overindulge in the middle of the week, Finestone said